Table 1.
Pathological and clinical characteristics of breast cancer samples in the training and validation sets.
| Training set (n = 61) |
Validation set (n = 299) |
|||||
|---|---|---|---|---|---|---|
| No IBC (%) | IBC (%) | p-valuea | No IBC (%) | IBC (%) | p-valuea | |
| Total | 28 (100) | 33 (100) | 155 (100) | 144 (100) | ||
| Age | ||||||
| ≤50 | 4 (14.3) | 16 (48.5) | 0.0046 | 33 (21.3) | 58 (40.3) | 0.00036 |
| >50 | 24 (85.7) | 17 (51.5) | 122 (78.7) | 86 (59.7) | ||
| SBR histological gradeb | ||||||
| I | 1 (3.6) | 0 (0.0) | 0.045c | 19 (12.5) | 2 (1.4) | <10−4d |
| II | 18 (64.3) | 12 (37.5) | 81 (53.3) | 56 (40.0) | ||
| III | 9 (32.1) | 20 (62.5) | 52 (34.2) | 82 (58.6) | ||
| Stage | ||||||
| I | 6 (21.4) | 0 (0.0) | – | 10 (6.5) | 0 (0.0) | – |
| IIA | 5 (17.9) | 0 (0.0) | 51 (32.9) | 0 (0.0) | ||
| IIB | 5 (17.9) | 0 (0.0) | 62 (40.0) | 0 (0.0) | ||
| IIIA | 5 (17.9) | 0 (0.0) | 30 (19.4) | 0 (0.0) | ||
| IIIB | 7 (25.0) | 24 (72.7) | 2 (1.3) | 115 (79.9) | ||
| IV | 0 (0.0) | 9 (27.3) | 0 (0.0) | 29 (20.1) | ||
| ER status | ||||||
| Negative | 6 (21.4) | 21 (65.6) | 0.00060c | 44 (28.4) | 77 (56.2) | <10−4d |
| Positive | 22 (78.6) | 11 (34.4) | 111 (71.6) | 60 (43.8) | ||
| PR status | ||||||
| Negative | 9 (32.1) | 24 (75.0) | 0.00087c | 69 (44.5) | 101 (74.3) | <10−4e |
| Positive | 19 (67.9) | 8 (25.0) | 86 (55.5) | 35 (25.7) | ||
| ERBB2 status | ||||||
| Negative | 23 (82.1) | 17 (53.1) | 0.017c | 127 (81.9) | 102 (73.4) | 0.078 |
| Positive | 5 (17.9) | 15 (46.9) | 28 (18.1) | 37 (26.6) | (NS) f | |
| Molecular subtypes | ||||||
| HR- ERBB2- | 3 (10.7) | 7 (21.9) | 0.0048c | 26 (16.8) | 44 (32.6) | <10−4h |
| HR- ERBB2+ | 2 (2.7) | 13 (40.6) | 15 (9.7) | 29 (21.5) | ||
| HR + ERBB2- | 20 (71.4) | 10 (31.3) | 101 (65.2) | 54 (40.0) | ||
| HR + ERBB2+ | 3 (10.7) | 2 (6.3) | 13 (8.4) | 8 (5.9) | ||
| Distant metastases | ||||||
| Yes | 12 (42.9) | 22 (66.7) | 0.062 | 54 (34.8) | 88 (61.1) | <10−4 |
| No | 16 (57.1) | 11 (33.3) | (NS) | 101 (65.2) | 56 (38.9) | |
Abbreviations: ER: estrogen receptor alpha; PR: progesterone receptor; ERBB2: human epidermal growth factor receptor 2; HR: hormone receptor. Bold values are statistically significant (p-value < 0.05). a Chi2 Test; b Scarff-Bloom-Richardson classification; c Information available for 60 patients; d Information available for 292 patients; e Information available for 291 patients; f Information available for 294 patients; h Information available for 290 patients.